A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors

Back to Search
Print
Bookmark Trial

NCT03854227

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Advanced Solid Tumors, Metastatic Solid Tumors
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histologically or cytologically confirmed locally advanced or metastatic NSCLC, urothelial carcinoma or HNSCC

- Progressed after at least 1 line of treatment and no more than 3 lines of treatment

- At least one measurable lesion as defined by RECIST version 1.1

- ECOG Performance Status 0 or 1

- Adequate Bone Marrow Function

- Adequate Renal Function

- Adequate Liver Function

- Resolved acute effects of any prior therapy

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Known active uncontrolled or symptomatic CNS metastases.


- Major surgery, radiation therapy, systemic anti-cancer therapy or investigational
drug(s) within 4 weeks prior to study entry.


- Active, uncontrolled infection, including COVID-19


- Known or suspected hypersensitivity to PF-06939999


- Inability to consume or absorb study drug

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Advanced Solid Tumors, Metastatic Solid TumorsA Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
NCT03854227
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
Official Title  ICMJE A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF-06939999 (PRMT5 INHIBITOR) IN PARTICIPANTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, HEAD AND NECK SQUAMOUS CELL CARCINOMA, ESOPHAGEAL CANCER, ENDOMETRIAL CANCER, CERVICAL CANCER AND BLADDER CANCER
Brief Summary This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:
Dose Escalation
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Advanced Solid Tumors
  • Metastatic Solid Tumors
Intervention  ICMJE
  • Drug: PF-06939999 dose escalation
    PF-06939999 orally at escalating doses on a continuous basis
    Other Name: PRMT5 inhibitor
  • Drug: PF-06939999 monotherapy
    PF-06939999 at the recommended Phase 2 dose orally on a continuous basis
    Other Name: PRMT5 inhibitor
  • Drug: PF-06939999 in combination with docetaxel
    PF-06939999 orally on a continuous basis in combination with docetaxel
    Other Name: PRMT5 inhibitor
Study Arms  ICMJE
  • Experimental: Dose Escalation
    Participants will receive PF-06939999 orally at escalating doses in 28 day cycles on a continuous basis
    Intervention: Drug: PF-06939999 dose escalation
  • Experimental: Non small cell lung cancer monotherapy
    Participants will receive PF-06939999 at the recommended Phase 2 dose in 28 day cycles on a continuous basis
    Intervention: Drug: PF-06939999 monotherapy
  • Experimental: Urothelial carcinoma
    Participants will receive PF-06939999 at the recommended Phase 2 dose in 28 day cycles on a continuous basis
    Intervention: Drug: PF-06939999 monotherapy
  • Experimental: Head and neck squamous cell carcinoma
    Participants will receive PF-06939999 at the recommended Phase 2 dose in 28 day cycles on a continuous basis
    Intervention: Drug: PF-06939999 monotherapy
  • Experimental: Non small cell lung cancer PF-06939999 plus docetaxel
    Participants will receive PF-06939999 on a continuous basis in combination with docetaxel
    Intervention: Drug: PF-06939999 in combination with docetaxel
  • Experimental: Non small cell lung cancer dose finding
    Participants will receive PF-06939999 on a continuous basis at escalating doses in combination with docetaxel
    Intervention: Drug: PF-06939999 in combination with docetaxel
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: September 1, 2020)		140
Original Estimated Enrollment  ICMJE
 (submitted: February 22, 2019)		50
Estimated Study Completion Date  ICMJE February 11, 2026
Estimated Primary Completion Date August 12, 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Histologically or cytologically confirmed locally advanced or metastatic NSCLC, urothelial carcinoma or HNSCC
  • Progressed after at least 1 line of treatment and no more than 3 lines of treatment
  • At least one measurable lesion as defined by RECIST version 1.1
  • ECOG Performance Status 0 or 1
  • Adequate Bone Marrow Function
  • Adequate Renal Function
  • Adequate Liver Function
  • Resolved acute effects of any prior therapy

Exclusion Criteria:

  • Known active uncontrolled or symptomatic CNS metastases.
  • Major surgery, radiation therapy, systemic anti-cancer therapy or investigational drug(s) within 4 weeks prior to study entry.
  • Active, uncontrolled infection, including COVID-19
  • Known or suspected hypersensitivity to PF-06939999
  • Inability to consume or absorb study drug
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Pfizer CT.gov Call Center1-800-718-1021[email protected]
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03854227
Other Study ID Numbers  ICMJE C3851001
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:No
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date September 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP